When transitioning from clinical/development to commercial for the first time, emerging biopharma companies are tasked with the implementation of over 100 new business capabilities, including the integration of 70+ systems and third parties. This can be a daunting, expensive, and intensive process for full-time employees (FTEs). SVA Consulting partners with executive teams and functional heads to reduce risk and manage uncertainty during these transitions.
We’re continuous learners and innovators with a passion for the commercialization and/or transactional journey of life science companies. Our service offerings capitalize on our past and present work with emerging biopharma companies, leveraging tools, templates, experience, knowledge, and relationships on your behalf to make this an exciting, rewarding, and successful experience as you take your next steps towards improving patient lives.
Our primary service offerings:
MyoKardia engaged SVA Consulting at the end of its Phase 3 program to evaluate the commercial capabilities of their financial systems. The question at hand was whether MyoKardia should take on the implementation of a new ERP system, or whether their current ERP system would support a commercial company.Read More
Exact Sciences was referred to SVA Consulting when they were a startup medical device company. In lightning speed of 19 months, Exact Sciences grew from 36 employees to over 700, moving from developing Cologuard, their pre-screening test for colon rectal cancer, to human trials, FDA approval and then to the international marketplace.Read More
Verastem was referred to SVA Consulting as a Phase 3 biopharmaceutical company with 30 employees and promising data. SVA was brought in to help Verastem Oncology with the launch planning around the operations and processes, as well as helping to plan all of Verastem’s systems, which prior to SVA, their “systems” were email and a server.Read More